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ABSTRACT 
The rapid emergence and spread of antimicrobial resistance has evolved to a major health care threat, which is 
further exacerbated by the diminished antibiotic development pipeline [1].  Lysins are a novel class of enzyme-
based antibiotics.  A portfolio review in 2016 ranked lysins, based on their clinical impact and technical feasibility, 
as the alternative class of antibiotics with the greatest potential [2].  Moreover, several lysins are currently under 
evaluation in clinical trials [3].  Here, we here report on the development of a novel microdroplet-based screening 
platform that can be used to identify customized lysins for each multi-drug resistant bacterium. 
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INTRODUCTION 
A unique feature of lysins is their modular structure, providing opportunities to customize lysins towards every 
patient’s bacterial isolate.  However, the current progress is empirical and hampered by tedious cloning procedures.  
To address this technical barrier, we developed a novel DNA shuffling method, coined VersaTile, enabling the 
generation of up to millions of variants in a single reaction.  Using an in-house microtiter-based screening method, 
we established a hit-to-lead development process for engineered lysins, similar to the development of 
pharmaceutical drugs (manuscript in preparation).  Still, this workflow only allowed the screening of than 0.01% 
of the total possible variants, clearly indicating the need for a more high-throughput screening method [4]. 
 
RESULTS AND DISCUSSION 
We here combine VersaTile with a custom developed ultra-high-throughput microfluidics-based screening 
workflow (Figure 1), facilitating the screening of the entire protein landscape.  This platform consists of three main 
modules: DNA amplification, lysin expression and selection of variants with antibacterial activity.  The different 
modules of the platform are fabricated using standard PDMS soft lithography techniques. 
 
 
 
Figure 1: Schematic workflow of the high-throughput, droplet-based microfluidic platform for screening engineered lysin 
variants.  The microfluidic unit operations are represented on top, and the effect of the operation on the content of individual 
droplets is shown below.  At first, each engineered lysin (DNA) is separately encapsulated in a microfluidic droplet, where it 
is amplified.  Pico-injecting an expression mixture in the droplets, ensures that each variant is produced.  The antibacterial 
activity of each variant is assessed by adding bacteria, and lysis of the bacteria will result in a fluorescent signal.  Finally, this 
fluorescent signal is used to sort out the active variant of which the specific structure is determined by sequencing in order to 
derive structure-activity-relationships that form the basis for the next engineering round. 
In the first module, a DNA library of engineered lysins is encapsulated inside 15 pL droplets according to 
Poisson statistics (Figure 2A), and each variant is amplified by rolling circle amplification (RCA) (Figure 2B).  In 
the second module, the expression of the engineered lysins is initiated by pico-injecting an in vitro transcription and 
translation mixture in each droplet.  In a third module, bacteria are injected into the droplets to assess the 
antibacterial activity of the expressed lysins.  Cell lysis activates fluorescence, correlating efficient lysis to a 
readable fluorescence signal.  The latter is used to sort out the fluorescent droplets out of the pool of negative 
variants. 
 
Figure 2: Comparison of theoretical Poisson distribution to our encapsulation of a DNA library of engineered lysins.  (A) 
The encapsulation of our engineered lysins (blue dots) follows the predict Poisson distribution (orange curve).  (B) After 
amplification of the engineered lysin, a clear DNA blob is seen.  The DNA was stained using Sybr Green. 
 
Via sequencing we then determine the building blocks of the engineered lysin.  With this information we derive 
the structure-activity-relationships (SARs), forming the basis for the next engineering round.  
 
CONCLUSION 
In summary, we have demonstrated a microfluidic approach to derive SARs from active engineered lysins.  We 
are now further characterizing these new engineered lysins regarding their antibacterial spectrum, stability, working 
mechanism, etc.  The combination of VersaTile and the microfluidics-based platform represents a key breakthrough 
for high-throughput lysin engineering and selection, and will facilitate the development of new designer lysins. 
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